Sobi recognised in the S&P Global Sustainability Yearbook 2025
Sobi has been included in the S&P Global Sustainability Yearbook 2025, a recognition of our commitment to sustainability and responsible business practices.
The S&P Global Corporate Sustainability Assessment (CSA) evaluates thousands of companies worldwide on their environmental, social, and governance (ESG) performance. This year, 7,690 companies were assessed, and only 780 across 62 industries were selected for the Yearbook. To be included, companies must rank within the top 15% of their industry and achieve a CSA Score within 30% of the industry’s top-performing company.
“At Sobi, sustainability is integral to how we operate and create lasting impact,” said Cecilia Nord, Global Head of Sustainability. “Being recognised in the S&P Global Sustainability Yearbook reinforces our commitment to responsible business and continuous progress in integrating sustainability into all aspects of our work.”
This achievement reflects the collective efforts of colleagues across Sobi in advancing sustainability and our dedication to improving the lives of people impacted by rare diseases while minimising our environmental footprint. We will continue strengthening our efforts, further embedding sustainability into our business, and striving to make a positive difference for patients and the communities we serve.
Read more about our approach to sustainability.
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.
- About
- Therapeutic areas
- Medicines
- Stories
- Sustainability
- Careers
- Investors
- Media
- English
- Swedish